azacitidine and Abnormalities, Autosome

azacitidine has been researched along with Abnormalities, Autosome in 72 studies

Research

Studies (72)

Timeframe	Studies, this research(%)	All Research%
pre-1990	8 (11.11)	18.7374
1990's	13 (18.06)	18.2507
2000's	14 (19.44)	29.6817
2010's	35 (48.61)	24.3611
2020's	2 (2.78)	2.80

Authors

Authors	Studies
Fujii, F; Kakinoki, Y; Matsuoka, S; Nojima, S	1
Dvořák Tomaštíková, E; Ercan, U; Finke, A; Krečmerová, M; Niezgodzki, I; Nowicka, A; Otmar, M; Pecinka, A; Poppenberger, B; Procházková, K; Rozhon, W; Schubert, I; Tokarz, B; Zwyrtková, J	1
Anguita, E; Bernal, T; Bulnes, PD; Colado, E; Garay, MCG; Gil, AC; Lopez-Larrea, C; Marin, AM; Márquez-Kisinousky, L; Minguela, A; Mogorron, AV; Raneros, AB; Rodriguez, RM; Suarez-Alvarez, B; Vidal-Castiñeira, JR	1
Adès, L; Ali, NH; Cluzeau, T; Eclache, V; Fenaux, P; Gyan, E; Hobson, S; Komrokji, RS; List, A; Prebet, T; Sanna, A; Santini, V; Sébert, M; Sekeres, MA	1
Dombret, H; Itzykson, R	1
Ame, S; Badiella, L; Bargay, J; Berthon, C; Beyne-Rauzy, O; Bordessoule, D; Cañizo, C; Cedena, T; de Botton, S; Delaunay, J; Díez-Campelo, M; Fenaux, P; Guieze, R; Gyan, E; Hernández-Rivas, JM; Isnard, F; Itzykson, R; López-Cadenas, F; Lorenzo, JI; Luño, E; Muñoz, JA; Park, S; Pérez Guallar, J; Perez-Oteyza, J; Rojas, SM; Salanoubat, C; Sanz, G; Stamatoullas, A; Such, E; Vey, N; Visanica, S	1
Arellano, M; Carlisle, JW	1
Chantepie, SP; Charbonnier, A; Gruson, B; Harrivel, V; Ivanoff, S; Lemasle, E; Marolleau, JP; Merlusca, L; Royer, B; Votte, P	1
Blau, IW; Böhme, A; Braulke, F; Brümmendorf, TH; Bug, G; Detken, S; Ganster, C; Germing, U; Giagounidis, AA; Götze, K; Haase, D; Hofmann, WK; Jentsch-Ullrich, K; Jung, K; Lübbert, M; Metz, M; Müller-Thomas, C; Ottmann, O; Pfeiffer, S; Platzbecker, U; Schafhausen, P; Schanz, J; Schlenk, RF; Schmidt, B; Seraphin, J; Shirneshan, K; Stadler, M; Trümper, L	1
Brioli, A; Davies, FE; Johnson, DC; Kaiser, MF; Melchor, L; Mirabella, F; Morgan, GJ; Walker, BA; Wardell, CP; Wu, P	1
Chang, C; He, Q; Li, X; Song, L; Su, J; Wu, D; Wu, L; Xu, F; Zhang, Q; Zhang, X; Zhang, Z; Zhou, L	1
Saunthararajah, Y	1
Li, J; Liu, J; Su, C; Tong, X; Zheng, D; Zhou, Z	1
Berthon, C; Delaunay, J; Dreyfus, F; Esterni, B; Fenaux, P; Itzykson, R; Kulasekararaj, A; Micol, JB; Mufti, G; Prebet, T; Recher, C; Roux, C; Sebert, M; Thepot, S; Vey, N; Wanquet, A	1
Goes, FS; Ishizuka, K; Kano, S; Koga, M; Kondo, MA; Obie, C; Passeri, E; Primerano, A; Rapoport, JL; Sawa, A; Sengupta, S; Srivastava, R; Valle, D; Wilson, AM; Zandi, PP	1
Braulke, F; Ganster, C; Haase, D; Platzbecker, U; Salinas-Riester, G; Schanz, J; Shirneshan, K	1
Garcia-Manero, G; Goswami, M; Hasserjian, RP; Jabbour, EJ; Medeiros, LJ; Patel, KP; Peng, J; Tang, G; Wang, SA	1
Dou, MH; Hu, C; Huang, J; Jin, J; Li, Y; Lou, YJ; Luo, YW; Ma, LY; Mao, LP; Mei, C; Niu, LM; Ren, YL; Tong, HY; Wang, JH; Wei, JY; Xie, LL; Xu, GX; Ye, L; Ye, XN; Yu, WJ; Zhou, XP	1
Harada, Y; Ito, M; Iwasaki, T; Kurahashi, S; Nishiwaki, S; Okuno, S; Sugiura, I; Suzuki, K; Watarai, R; Yamamoto, S	1
Barra, V; Cilluffo, D; Costa, G; Di Leonardo, A; Lentini, L	1
Aoyama, Y; Hino, M; Ichihara, H; Ido, K; Manabe, M; Mugitani, A; Nagasaki, J; Ohta, T	1
Ando, T; Kimura, S; Kizuka, H; Kojima, K; Kubota, Y; Kusaba, K; Nishioka, A; Sano, H; Shindo, T; Ureshino, H	1
Chang, CK; Guo, J; He, Q; Li, X; Song, LX; Su, JY; Wu, D; Wu, LY; Xiao, C; Xu, F; Zhang, Z; Zhao, YS	1
Chang, CK; Guo, J; Li, X; Song, LL; Wu, D; Wu, LY; Xiao, C; Xu, F; Zhao, YS	1
Borthakur, G; Cortes, J; Faderl, S; Garcia-Manero, G; Issa, JP; Kantarjian, H; O'Brien, S; Pierce, S; Ravandi, F; Shan, J; Verstovsek, S	1
Artigas, R; de Bethencourt, M; Iriarte, A; Iriarte, W; Llambí, S; Postiglioni, A	1
Braulke, F; Haase, D; Jung, K; Schanz, J; Schuetze, C; Schulte, K; Shirneshan, K; Steffens, R; Trümper, L	1
Manna, S; Mukherjee, P; Mukherjee, S; Pal, D; Panda, CK	1
Afable, M; Cuthbertson, D; Ganetsky, R; Ganetzky, R; Latham, D; List, AF; Loughran, TP; Maciejewski, JP; Paquette, R; Paulic, K; Saba, HI; Sekeres, MA	1
Ebert, BL	1
Castoro, R; Chung, W; El Ahdab, S; He, R; Issa, JP; Jelinek, J; Kantarjian, HM; Qin, T; Shu, J; Si, J; Wang, X; Zhang, N	1
Horiike, S; Kuroda, J; Nagoshi, H; Taniwaki, M	1
Chan, KW; Lockhart, S; McDonald, L; Rytting, M	1
Castro, C; Fabián, E; González, R; Herrera, LA; Prada, D; Sánchez, L	1
Parikh, SA; Tefferi, A	1
Barreyro, L; Ben-Neriah, S; Bhagat, TD; Bhattacharyya, S; Boultwood, J; Greally, JM; Heuck, C; List, AF; Maciejewski, J; McMahon, C; Mo, Y; Montagna, C; Parekh, S; Pellagatti, A; Schinke, C; Silverman, L; Steidl, C; Steidl, U; Tamari, R; Verma, A; Vogler, TO; Will, B; Ye, BH; Yu, Y; Zhou, L	1
Ritchie, EK	1
Akria, L; Arad, A; Aviv, A; Braester, A; Dally, N; Filanovsky, K; Gafter-Gvili, A; Gatt, ME; Hellmann, I; Herishanu, Y; Herzog-Tzarfati, K; Leiba, R; Merkel, D; Mittelman, M; Nagler, A; Nemets, A; Ofran, Y; Ronson, A; Rouvio, O; Silbershatz, I; Tadmor, T; Vidal, L; Yeganeh, S	1
Cardoso, RS; Dias, FL; Guimarães, AP; Kronka, SN; Sakamoto-Hojo, ET	1
Baker, E; Sutherland, GR	1
Giles, FJ; Jabbour, EJ	1
Flores-Morales, A; Johansson, B; Larsson, C; Nilsson, P; Norstedt, G; Pang, ST; Pourian, MR; Pousette, A; Weng, WH	1
Hackanson, B; Lübbert, M; Robbel, C; Wijermans, P	1
Bouabdallah, K; Daskalakis, M; Johansson, B; Kunzmann, R; Lübbert, M; Mauritzson, N; Müller-Berndorff, H; Onida, F; Schmitt-Gräff, A	1
Nimer, SD	1
Aribi, A; Cortes, J; Davisson, J; Garcia-Manero, G; Issa, JP; Jabbour, E; Kantarjian, HM; O'Brien, S; Ravandi, F; Shan, J	1
Habano, W; Jiao, YF; Nakamura, S; Sugai, T	1
Chronis, C; Ho, A; John, A; Khan, S; Mufti, GJ; Pomplun, S; Raj, K; Samuel, J; Thomas, NS	1
Seifertová, M	1
Golomb, HM; Larson, RA; Rowley, JD; Sweet, DL; Testa, JR	1
Anisowicz, A; Gadi, IK; Harrison, JJ; Raffeld, M; Sager, R	1
Gadi, IK; Harrison, JJ; Sager, R	1
Campos, A; Fernández, JL; Gosálvez, J; Goyanes, V; Pereira, S	1
Bourgeois, CA; Delattre, JY; Dutrillaux, AM; Dutrillaux, B; Kokalj-Vokac, N; Malfoy, B; Poisson, M; Vega, F	1
Hagemeijer, A; Hoebee, B; Honders, MW; Landegent, JE; Stegmann, AP; Willemze, R	1
Almeida, A; Dutrillaux, B; Jeanpierre, M; Kokalj-Vokac, N; Malfoy, B; Viegas-Péquignot, E	1
Ehrlich, M; Frady, A; Hernandez, R; Ji, W; Qu, GZ; Varela, M; Zhang, XY	1
Cortés, F; López-Baena, M; Mateos, S; Piñero, J	1
Eastmond, DA; Grosovsky, AJ; Hasegawa, LS; Parks, KK; Smith, LE	1
Hahn, PJ; Rizwana, R	1
Sakamoto-Hojo, ET; Takahashi, CS; Takahashi-Hyodo, SA	1
Hallett, WH; Vig, BK	1
Camitta, B; Carroll, AJ; Chang, M; Gresik, MV; Raimondi, SC; Ravindranath, Y; Steuber, CP; Weinstein, H	1
Andre, M; Bosly, A; Ferrant, A; Kunzmann, R; Lübbert, M; Ravoet, C; Verhoef, G; Wijermans, P	1
Dutrillaux, B; Viegas-Péquignot, E	1
Alexander, B; Berger, R; Cook, WD; Day, LM; Feneziani, A; Hogarth, PM	1
Crowther, P; Davidson, S; Radley, J; Woodcock, D	1
Abella, E; Alvarado, CS; Chauvenet, A; Dubowy, R; Harris, M; Inoue, S; Krischer, JP; Ravindranath, Y; Ritchey, AK; Wiley, J	1
Lutze, LH; Morgan, WF; Phillips, JW; Winegar, RA	1
Jenssen, D; Zhang, LH	1
Ferraro, M; Lavia, P; Micheli, A; Olivieri, G	1
Benedict, WF; Karon, M	1

Reviews

11 review(s) available for azacitidine and Abnormalities, Autosome

Article	Year
How and when to decide between epigenetic therapy and chemotherapy in patients with AML. Hematology. American Society of Hematology. Education Program, 2017, 12-08, Volume: 2017, Issue:1 Topics: Azacitidine; Chromosome Aberrations; Decision Making; Decitabine; Epigenesis, Genetic; Humans; Leukemia, Myeloid, Acute	2017
How I treat older patients with acute myeloid leukemia. Cancer, 2018, 06-15, Volume: 124, Issue:12 Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Cytarabine; Decitabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Histone Deacetylase Inhibitors; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Prognosis; Remission Induction; Survival Rate; Transplantation, Homologous	2018
Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes. Hematology. American Society of Hematology. Education Program, 2013, Volume: 2013 Topics: Azacitidine; Cell Proliferation; Chromosome Aberrations; Decitabine; Disease-Free Survival; DNA-Cytosine Methylases; Enzyme Inhibitors; Gene Expression Regulation; Humans; Myelodysplastic Syndromes; S Phase; Survival Rate; Transcription Factors	2013
5q- syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10). International journal of hematology, 2017, Volume: 105, Issue:5 Topics: Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 5; Fatal Outcome; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Translocation, Genetic	2017
Cytogenetic and molecular abnormalities in myelodysplastic syndrome. Current molecular medicine, 2011, Volume: 11, Issue:8 Topics: Animals; Antineoplastic Agents; Azacitidine; Chromosome Aberrations; Humans; Lenalidomide; Mutation; Myelodysplastic Syndromes; Thalidomide	2011
Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management. American journal of hematology, 2012, Volume: 87, Issue:6 Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Examination; Chromosome Aberrations; Clinical Trials as Topic; Combined Modality Therapy; Decitabine; Diagnosis, Differential; Disease Management; Female; Genes, Neoplasm; Humans; Leukemia, Myelomonocytic, Chronic; Leukocyte Count; Male; Risk Assessment; Stem Cell Transplantation; Transplantation, Homologous	2012
Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome. Clinical interventions in aging, 2012, Volume: 7 Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Cytarabine; Disease Progression; Drug Evaluation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Outcome Assessment, Health Care; Quality of Life; Risk Assessment; Sickness Impact Profile	2012
Forgotten fragile sites and related phenomena. Cytogenetic and genome research, 2003, Volume: 100, Issue:1-4 Topics: Antimetabolites, Antineoplastic; Azacitidine; Bromodeoxyuridine; Chromosome Aberrations; Chromosome Fragile Sites; Cytogenetic Analysis; Humans	2003
New agents in myelodysplastic syndromes. Current hematology reports, 2005, Volume: 4, Issue:3 Topics: Alkyl and Aryl Transferases; Angiogenesis Inhibitors; Apoptosis; Arsenicals; Azacitidine; Benzamides; Chromosome Aberrations; Clinical Trials as Topic; Cytokines; DNA Methylation; Enzyme Inhibitors; Farnesyltranstransferase; Growth Substances; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunosuppressive Agents; Myelodysplastic Syndromes; Oligonucleotides, Antisense; Piperazines; Prognosis; Pyrimidines; Treatment Outcome	2005
In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies. Annals of hematology, 2005, Volume: 84 Suppl 1 Topics: Acute Disease; Animals; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Clinical Trials as Topic; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA Methylation; Epigenesis, Genetic; Humans; Leukemia, Myeloid; Mice; Myelodysplastic Syndromes	2005
Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-01, Volume: 24, Issue:16 Topics: Anemia, Hypochromic; Azacitidine; Bone Marrow; Chromosome Aberrations; Chromosomes, Human, Pair 5; Erythrocyte Transfusion; Erythropoiesis; Erythropoietin; Gene Deletion; Hematinics; Hematopoietic Stem Cell Transplantation; Humans; Karyotyping; Lenalidomide; Myelodysplastic Syndromes; Predictive Value of Tests; Prognosis; Randomized Controlled Trials as Topic; Recombinant Proteins; Thalidomide	2006

Trials

5 trial(s) available for azacitidine and Abnormalities, Autosome

Article	Year
Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries. British journal of haematology, 2018, Volume: 181, Issue:3 Topics: Aged; Azacitidine; Chromosome Aberrations; Chromosomes, Human, Pair 7; Disease-Free Survival; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Registries; Retrospective Studies; Risk Factors; Survival Rate	2018
Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study. Leukemia research, 2013, Volume: 37, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Chromosome Banding; Female; Follow-Up Studies; Germany; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Thalidomide; Time Factors; Treatment Outcome	2013
Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, May-01, Volume: 28, Issue:13 Topics: Aged; Azacitidine; Chromosome Aberrations; DNA Methylation; DNA Modification Methylases; DNA Mutational Analysis; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Karyotyping; Lenalidomide; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Precancerous Conditions; Risk Assessment; Thalidomide; Time Factors; Treatment Outcome; United States	2010
Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer, 2007, Jan-15, Volume: 109, Issue:2 Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Chromosomes, Human, Pair 5; Chromosomes, Human, Pair 7; Decitabine; Drug Administration Schedule; Fatigue; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Prognosis; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome; Vomiting	2007
CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia, 2007, Volume: 21, Issue:9 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Bone Marrow Cells; Chromosome Aberrations; Chromosomes, Human, Pair 7; Cyclin-Dependent Kinase Inhibitor p15; DNA Methylation; Female; Genetic Markers; Humans; Injections, Subcutaneous; Male; Middle Aged; Myelodysplastic Syndromes; Predictive Value of Tests; Promoter Regions, Genetic; Survival Rate; Treatment Outcome	2007

Other Studies

56 other study(ies) available for azacitidine and Abnormalities, Autosome

Article	Year
[Prompt cytogenetic response by venetoclax plus azacitidine regimen in a patient with AML harboring double-minute chromosomes with MYC gene amplification]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2023, Volume: 64, Issue:7 Topics: Aged, 80 and over; Azacitidine; Chromosome Aberrations; Chromosomes; Female; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute	2023
Comparative analysis of epigenetic inhibitors reveals different degrees of interference with transcriptional gene silencing and induction of DNA damage. The Plant journal : for cell and molecular biology, 2020, Volume: 102, Issue:1 Topics: Adenosine; Arabidopsis; Azacitidine; Chromosome Aberrations; Cytidine; Decitabine; DNA Damage; DNA Methylation; DNA Repair; Epigenesis, Genetic; Gene Silencing; Heterochromatin; RNA Interference; Tandem Repeat Sequences	2020
Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition. Oncotarget, 2017, 05-09, Volume: 8, Issue:19 Topics: ADAM17 Protein; Adult; Aged; Azacitidine; Cell Line, Tumor; Chromosome Aberrations; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Leukemic; GPI-Linked Proteins; Histocompatibility Antigens Class I; Humans; Intercellular Signaling Peptides and Proteins; Killer Cells, Natural; Leukemia, Myeloid, Acute; Male; Middle Aged; NK Cell Lectin-Like Receptor Subfamily K; Prognosis; Tissue Inhibitor of Metalloproteinase-3	2017
Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine. Leukemia research, 2017, Volume: 63 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Female; Follow-Up Studies; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Remission Induction; Risk Factors; Survival Rate	2017
5-Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy. American journal of hematology, 2013, Volume: 88, Issue:7 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Cells; Chromosome Aberrations; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Nuclear Proteins; Nucleophosmin; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome	2013
Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma. Blood, 2013, Jul-11, Volume: 122, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Chromosome Aberrations; Decitabine; Disease Progression; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Male; Middle Aged; Multiple Myeloma; Osteonectin; Phenotype; Prognosis; Transforming Growth Factor beta1; Tumor Suppressor Proteins	2013
Cytogenetic response based on revised IPSS cytogenetic risk stratification and minimal residual disease monitoring by FISH in MDS patients treated with low-dose decitabine. Leukemia research, 2013, Volume: 37, Issue:11 Topics: Abnormal Karyotype; Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Cytogenetic Analysis; Decitabine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Prognosis; Risk Assessment; Survival Rate	2013
Efficacy and side-effects of decitabine in treatment of atypical chronic myeloid leukemia. Leukemia & lymphoma, 2015, Volume: 56, Issue:6 Topics: Adult; Anemia; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Decitabine; Fatal Outcome; Female; Humans; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Remission Induction; Thrombocytopenia; Treatment Outcome	2015
Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities. American journal of hematology, 2015, Volume: 90, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Allografts; Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Chromosome Aberrations; Chromosomes, Human, Pair 3; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Stem Cell Transplantation; Survival Rate	2015
Enhanced conversion of induced neuronal cells (iN cells) from human fibroblasts: Utility in uncovering cellular deficits in mental illness-associated chromosomal abnormalities. Neuroscience research, 2015, Volume: 101 Topics: Adolescent; Adult; Azacitidine; Cell Culture Techniques; Cell Differentiation; Chromosome Aberrations; Culture Media; Female; Fibroblasts; Humans; Hydroxamic Acids; Induced Pluripotent Stem Cells; Male; Middle Aged; Neural Stem Cells; Schizophrenia; Valproic Acid; Young Adult	2015
Influence of total genomic alteration and chromosomal fragmentation on response to a combination of azacitidine and lenalidomide in a cohort of patients with very high risk MDS. Leukemia research, 2015, Volume: 39, Issue:10 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Female; Humans; Kaplan-Meier Estimate; Karyotyping; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Oligonucleotide Array Sequence Analysis; Proportional Hazards Models; Thalidomide; Tumor Suppressor Protein p53	2015
Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response. Leukemia & lymphoma, 2016, Volume: 57, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biopsy; Bone Marrow; Chromosome Aberrations; Decitabine; DNA Methylation; Female; Humans; In Situ Hybridization, Fluorescence; Leukemia, Erythroblastic, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Survival Analysis; Treatment Outcome; Young Adult	2016
Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms. Leukemia & lymphoma, 2016, Volume: 57, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Cytarabine; Decitabine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Recurrence; Remission Induction; Treatment Outcome	2016
A new prognostic index to make short-term prognoses in MDS patients treated with azacitidine: A combination of p53 expression and cytogenetics. Leukemia research, 2016, Volume: 41 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Chromosome Aberrations; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Treatment Outcome; Tumor Suppressor Protein p53	2016
DNA demethylation caused by 5-Aza-2'-deoxycytidine induces mitotic alterations and aneuploidy. Oncotarget, 2016, Jan-26, Volume: 7, Issue:4 Topics: Aneuploidy; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Blotting, Western; Cell Proliferation; Chromosome Aberrations; Colonic Neoplasms; Cytogenetic Analysis; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Microscopy, Fluorescence; Mitosis; Ploidies; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured	2016
Wilms Tumor 1 (WT1) mRNA Expression Level at Diagnosis Is a Significant Prognostic Marker in Elderly Patients with Myelodysplastic Syndrome. Acta haematologica, 2017, Volume: 137, Issue:1 Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers; Bone Marrow Cells; Chromosome Aberrations; Female; Gene Expression; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Research Design; Retrospective Studies; Risk Factors; RNA, Messenger; Survival Analysis; WT1 Proteins	2017
TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes. British journal of haematology, 2017, Volume: 176, Issue:4 Topics: Azacitidine; Cell Transformation, Neoplastic; Chromosome Aberrations; Decitabine; Humans; Leukemia, Myeloid, Acute; Mutation; Myelodysplastic Syndromes; Predictive Value of Tests; Recurrence; Remission Induction; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53	2017
[Predict response to decitabine in patients with myelodysplastic syndrome and related neoplasms]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2017, Feb-14, Volume: 38, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Chromosome Aberrations; Chromosomes, Human, Pair 7; Decitabine; Female; Humans; Karyotype; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Neoplasms; Remission Induction; Retrospective Studies; Young Adult	2017
Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer, 2009, Dec-15, Volume: 115, Issue:24 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Chromosomes, Human, Pair 5; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome	2009
Effects of 5-azacytidine on lymphocyte-metaphases of Creole cows carrying the rob(1;29). Research in veterinary science, 2010, Volume: 88, Issue:2 Topics: Animals; Azacitidine; Cattle; Chromosome Aberrations; Heterozygote; Karyotyping; Lymphocytes; X Chromosome	2010
FISH analysis of circulating CD34+ cells as a new tool for genetic monitoring in MDS: verification of the method and application to 27 MDS patients. Leukemia research, 2010, Volume: 34, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Azacitidine; Bone Marrow Cells; Chromosome Aberrations; Chromosomes, Human, Pair 7; Female; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Monosomy; Myelodysplastic Syndromes	2010
Sequential loss of cell cycle checkpoint control contributes to malignant transformation of murine embryonic fibroblasts induced by 20-methylcholanthrene. Journal of cellular physiology, 2010, Volume: 224, Issue:1 Topics: Aneuploidy; Animals; Antimetabolites; Azacitidine; Carcinogens; Cell Cycle; Cell Cycle Proteins; Cell Line; Cell Proliferation; Cell Transformation, Neoplastic; Chromosome Aberrations; Decitabine; DNA Damage; DNA Methylation; Embryo, Mammalian; Epigenesis, Genetic; Fibroblasts; Gene Expression Regulation, Neoplastic; Genotype; Gestational Age; Methylcholanthrene; Mice; Phenotype; Phosphorylation; Signal Transduction	2010
Preface. The biology and treatment of myelodysplastic syndrome. Hematology/oncology clinics of North America, 2010, Volume: 24, Issue:2 Topics: Azacitidine; Bone Marrow Transplantation; Chromosome Aberrations; Drugs, Investigational; Epigenesis, Genetic; Humans; Mutation; Myelodysplastic Syndromes	2010
Mechanisms of resistance to decitabine in the myelodysplastic syndrome. PloS one, 2011, Volume: 6, Issue:8 Topics: Aged; Aged, 80 and over; Azacitidine; Chromosome Aberrations; CpG Islands; Cytidine Deaminase; Decitabine; Deoxycytidine Kinase; DNA Methylation; Drug Resistance; Female; Gene Expression Regulation; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA	2011
Clonal cytogenetic abnormalities after tyrosine kinase inhibitor therapy in Ph+ ALL resolution after decitabine therapy. Pediatric blood & cancer, 2012, Volume: 59, Issue:3 Topics: Azacitidine; Benzamides; Child, Preschool; Chromosome Aberrations; Decitabine; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Stem Cell Transplantation	2012
Satellite 2 demethylation induced by 5-azacytidine is associated with missegregation of chromosomes 1 and 16 in human somatic cells. Mutation research, 2012, Jan-03, Volume: 729, Issue:1-2 Topics: Azacitidine; Chromosome Aberrations; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 16; DNA Methylation; DNA, Satellite; Humans; Lymphocytes; Sulfites	2012
Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood, 2012, Sep-06, Volume: 120, Issue:10 Topics: Antigens, CD; Azacitidine; Case-Control Studies; Cell Lineage; Chromosome Aberrations; Chromosomes, Human, Pair 7; DNA Methylation; Epigenesis, Genetic; Flow Cytometry; Gene Expression; Hematopoietic Stem Cells; Humans; Karyotyping; Myelodysplastic Syndromes; Primary Cell Culture; Recurrence; STAT3 Transcription Factor	2012
Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study. American journal of hematology, 2013, Volume: 88, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Disease Susceptibility; Female; Humans; Incidence; Infections; Israel; Leukemia, Myeloid, Acute; Male; Methylation; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Retrospective Studies; Risk Factors; Severity of Illness Index; Thrombocytopenia	2013
Chromosomal aberrations induced by 5-azacytidine combined with VP-16 (etoposide) in CHO-K1 and XRS-5 cell lines. Teratogenesis, carcinogenesis, and mutagenesis, 2003, Volume: Suppl 1 Topics: Animals; Azacitidine; Cell Cycle; Cell Line; CHO Cells; Chromosome Aberrations; Cricetinae; Cytogenetic Analysis; Drug Combinations; Drug Interactions; Etoposide; Kinetics; Mutagens; Radiation Tolerance	2003
Cytogenetic and expression profiles associated with transformation to androgen-resistant prostate cancer. The Prostate, 2006, Feb-01, Volume: 66, Issue:2 Topics: Androgens; Azacitidine; Cell Line, Tumor; Chromosome Aberrations; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 2; Decitabine; Disease Progression; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Gene Expression; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Methyltransferases; Nucleic Acid Hybridization; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Spectral Karyotyping	2006
Trisomy 19 as the sole chromosomal abnormality in proliferative chronic myelomonocytic leukemia. Leukemia research, 2006, Volume: 30, Issue:8 Topics: Aged; Azacitidine; Chromosome Aberrations; Chromosomes, Human, Pair 19; Cytarabine; Cytogenetic Analysis; Daunorubicin; Decitabine; Dose-Response Relationship, Drug; Fatal Outcome; Female; Humans; Hydroxyurea; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Phenotype; Steroids; Treatment Outcome	2006
Novel approach for detecting global epigenetic alterations associated with tumor cell aneuploidy. International journal of cancer, 2007, Oct-01, Volume: 121, Issue:7 Topics: Aneuploidy; Azacitidine; Cell Line, Tumor; Cell Separation; Chromosome Aberrations; CpG Islands; Cytogenetics; Diploidy; DNA Methylation; DNA Mutational Analysis; DNA-Binding Proteins; DNA, Neoplasm; HCT116 Cells; HT29 Cells; Humans; Loss of Heterozygosity; Mutation; Neoplasms; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Reproducibility of Results; Transcription Factors; Zinc Fingers	2007
Karyotypes of the 5-azacytidine-sensitive and -resistant line of AKR mouse leukemia. Neoplasma, 1981, Volume: 28, Issue:3 Topics: Animals; Azacitidine; Cell Line; Cell Survival; Chromosome Aberrations; Drug Resistance; Female; Karyotyping; Leukemia, Experimental; Leukemia, Lymphoid; Mice; Mice, Inbred AKR	1981
Response to 5-azacytidine in patients with refractory acute nonlymphocytic leukemia and association with chromosome findings. Cancer, 1982, Jun-01, Volume: 49, Issue:11 Topics: Adult; Azacitidine; Bone Marrow; Chromosome Aberrations; Chromosome Disorders; Chromosomes, Human, 21-22 and Y; Chromosomes, Human, 6-12 and X; Female; Follow-Up Studies; Humans; Karyotyping; Leukemia, Lymphoid; Male; Middle Aged; Translocation, Genetic	1982
Azacytidine-induced tumorigenesis of CHEF/18 cells: correlated DNA methylation and chromosome changes. Proceedings of the National Academy of Sciences of the United States of America, 1983, Volume: 80, Issue:21 Topics: Adipose Tissue; Animals; Azacitidine; Cell Line; Chromosome Aberrations; Chromosome Disorders; Cricetinae; DNA, Neoplasm; Karyotyping; Methylation; Mice; Mice, Nude; Neoplasms, Experimental; Trisomy	1983
Genetic analysis of tumorigenesis: XVI. Chromosome changes in azacytidine- and insulin-induced tumorigenesis. Somatic cell and molecular genetics, 1984, Volume: 10, Issue:5 Topics: Animals; Azacitidine; Carcinogens; Cell Line; Cell Transformation, Neoplastic; Chromosome Aberrations; Chromosome Banding; Chromosome Disorders; Cricetinae; Cricetulus; Embryo, Mammalian; Insulin; Karyotyping; Neoplasms, Experimental	1984
An extra band within the human 9qh+ region that behaves like the surrounding constitutive heterochromatin. Journal of medical genetics, 1994, Volume: 31, Issue:8 Topics: 5-Methylcytosine; Adult; Azacitidine; Chromosome Aberrations; Chromosome Banding; Chromosomes, Human; Chromosomes, Human, Pair 9; Cytosine; Heterochromatin; Humans; In Situ Hybridization, Fluorescence; Lymphocytes; Male; Methylation; Microscopy, Electron	1994
[Characterization of chromosomal rearrangements by in situ hybridization in glioblastoma]. Bulletin du cancer, 1994, Volume: 81, Issue:5 Topics: Azacitidine; Chromosome Aberrations; Chromosome Mapping; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 9; DNA, Neoplasm; DNA, Satellite; Glioblastoma; Heterochromatin; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Male; Methylation; Middle Aged; Tumor Cells, Cultured	1994
In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2'-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene. Annals of hematology, 1995, Volume: 71, Issue:1 Topics: Animals; Antineoplastic Agents; Azacitidine; Base Sequence; Chromosome Aberrations; Cytarabine; Decitabine; Deoxycytidine Kinase; Drug Resistance; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Molecular Sequence Data; Point Mutation; Polymorphism, Single-Stranded Conformational; Rats; Translocation, Genetic; Tumor Cells, Cultured	1995
Specific induction of uncoiling and recombination by azacytidine in classical satellite-containing constitutive heterochromatin. Cytogenetics and cell genetics, 1993, Volume: 63, Issue:1 Topics: Azacitidine; Cell Transformation, Neoplastic; Cells, Cultured; Chromosome Aberrations; Chromosome Banding; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 16; DNA; DNA Damage; DNA, Satellite; Heterochromatin; Humans; In Situ Hybridization, Fluorescence; Lymphocytes; Methylation; Nucleic Acid Denaturation	1993
DNA demethylation and pericentromeric rearrangements of chromosome 1. Mutation research, 1997, Sep-05, Volume: 379, Issue:1 Topics: Adult; Azacitidine; B-Lymphocytes; Burkitt Lymphoma; Cell Line; Cell Line, Transformed; Centromere; Chromosome Aberrations; Chromosome Disorders; Chromosomes, Human, Pair 1; Decitabine; DNA Methylation; DNA, Satellite; Face; Fibroblasts; Heterochromatin; Humans; Immunologic Deficiency Syndromes; Male; Stem Cells; Tumor Cells, Cultured	1997
Enhanced sensitivity to topoisomerase inhibitors in synchronous CHO cells pre-treated with 5-azacytidine. Mutation research, 1998, Oct-12, Volume: 421, Issue:1 Topics: Amsacrine; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Azacitidine; Camptothecin; CHO Cells; Chromosome Aberrations; Cricetinae; DNA Methylation; Drug Interactions; Enzyme Inhibitors; S Phase; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors	1998
Targeted breakage of paracentromeric heterochromatin induces chromosomal instability. Mutagenesis, 1998, Volume: 13, Issue:5 Topics: 2-Aminopurine; Adenine Phosphoribosyltransferase; Azacitidine; B-Lymphocytes; Cell Line; Centromere; Chromosome Aberrations; Chromosomes, Human; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 17; DNA Damage; Heterochromatin; Humans; Hypoxanthine Phosphoribosyltransferase; In Situ Hybridization, Fluorescence; Interphase; Metaphase; Thymidine Kinase	1998
CpG methylation reduces genomic instability. Journal of cell science, 1999, Volume: 112 ( Pt 24) Topics: Animals; Azacitidine; Cell Line; Chromosome Aberrations; CpG Islands; Dimerization; DNA Methylation; Metaphase; Mice	1999
Interaction effects of 5-azacytidine with topoisomerase II inhibitors on CHO cells, as detected by cytogenetic analysis. Mutation research, 1999, Dec-16, Volume: 431, Issue:1 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle; CHO Cells; Chromosome Aberrations; Cricetinae; Drug Interactions; Ellipticines; Enzyme Inhibitors; Teniposide; Topoisomerase II Inhibitors	1999
5-Azacytidine- and Hoechst-induced aneuploidy in Indian muntjac. Mutation research, 2000, Mar-03, Volume: 466, Issue:1 Topics: Aneuploidy; Animals; Azacitidine; Bisbenzimidazole; Cells, Cultured; Chromosome Aberrations; Karyotyping; Male; Muntjacs; Y Chromosome	2000
Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome and acute promyelocytic leukemia): univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study Leukemia, 2000, Volume: 14, Issue:7 Topics: Adolescent; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Child; Chromosome Aberrations; Chromosome Inversion; Chromosomes, Human; Cohort Studies; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Life Tables; Male; Multicenter Studies as Topic; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Remission Induction; Risk Assessment; Risk Factors; Survival Analysis; Thioguanine; Translocation, Genetic; Treatment Failure; Treatment Outcome; United States	2000
Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine. British journal of haematology, 2001, Volume: 114, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Anemia, Sideroblastic; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Chromosome Disorders; Decitabine; Drug Administration Schedule; Female; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Risk; Survival Rate	2001
Segmentation of human chromosomes induced by 5-ACR (5-azacytidine). Human genetics, 1976, Dec-15, Volume: 34, Issue:3 Topics: Azacitidine; Azure Stains; Bromodeoxyuridine; Cells, Cultured; Chromosome Aberrations; Chromosomes; Humans; Lymphocytes; Staining and Labeling	1976
Tumor-associated karyotypic lesions coselected with in vitro macrophage differentiation. Genes, chromosomes & cancer, 1992, Volume: 5, Issue:4 Topics: Abelson murine leukemia virus; Animals; Azacitidine; Biomarkers, Tumor; Bromodeoxyuridine; Cell Adhesion; Cell Differentiation; Cell Transformation, Viral; Chromosome Aberrations; Dexamethasone; Hematopoietic Stem Cells; Hydroxyurea; Karyotyping; Leukemia, Experimental; Macrophages; Mice; Selection, Genetic; Thymus Neoplasms; Tumor Cells, Cultured	1992
Cytotoxicity of 5-aza-2'-deoxycytidine in a mammalian cell system. European journal of cancer (Oxford, England : 1990), 1992, Volume: 28, Issue:2-3 Topics: Animals; Antineoplastic Agents; Azacitidine; Cell Cycle; Cells, Cultured; Chromosome Aberrations; Cricetinae; Cricetulus; Decitabine; DNA; Female; Methylation; Ovary	1992
Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood, 1992, Nov-01, Volume: 80, Issue:9 Topics: Acute Disease; Adolescent; Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Azacitidine; Child; Chromosome Aberrations; Chromosome Disorders; Cytarabine; Daunorubicin; Down Syndrome; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Mercaptopurine; Methotrexate; Prednisone; Remission Induction; Thioguanine; Vincristine	1992
Chromosome aberration induction in Chinese hamster ovary cells by restriction enzymes with different methylation sensitivity. Somatic cell and molecular genetics, 1990, Volume: 16, Issue:3 Topics: Animals; Azacitidine; Cell Line; Chromosome Aberrations; Cricetinae; Cytosine; Decitabine; Deoxyribonuclease HpaII; Deoxyribonucleases, Type II Site-Specific; DNA; Methylation; Substrate Specificity	1990
Isolation and characterization of spontaneously occurring mutations at the HPRT locus in V79 Chinese hamster cells. Mutation research, 1989, Volume: 212, Issue:2 Topics: Animals; Azacitidine; Cell Line; Chromosome Aberrations; Cricetinae; Cricetulus; Ethyl Methanesulfonate; Ethylnitrosourea; Hypoxanthine Phosphoribosyltransferase; In Vitro Techniques; Mutation; Sodium-Potassium-Exchanging ATPase	1989
Effect of 5-azacytidine (5-azaC) on the induction of chromatid aberrations (CA) and sister-chromatid exchanges (SCE). Mutation research, 1985, Volume: 149, Issue:3 Topics: Azacitidine; Cells, Cultured; Chromatids; Chromosome Aberrations; Drug Synergism; Humans; Lymphocytes; Male; Mitomycin; Mitomycins; Sister Chromatid Exchange; X-Rays	1985
Chromatid breakage: differential effect of inhibitors of DNA synthesis during G 2 phase. Science (New York, N.Y.), 1972, Oct-06, Volume: 178, Issue:4056 Topics: Animals; Azacitidine; Azaguanine; Cell Line; Chromatids; Chromosome Aberrations; Cricetinae; Cytarabine; Cytidine; DNA; DNA Nucleotidyltransferases; Hydroxyurea; Lung; Mitosis; Oxidoreductases; Pyridines; Ribonucleotides; Thiosemicarbazones; Triazines	1972